Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESPIRARE: Cudetaxestat in Idiopathic Pulmonary Fibrosis
NCT05373914Phase 2Unknown
- Sponsor
- Blade Therapeutics, Inc.
- Start
- May 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of cudetaxestat in idiopathic pulmonary fibrosis (IPF) (4 arms), sponsored by Blade Therapeutics, Inc. Primary endpoint: Observed changes in Forced Vital Capacity at 26 weeks. Status: unknown.
02
Drugs
cudetaxestat
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT05373914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05373914.